GlaxoSmithKline (LON:GSK) had its target price cut by analysts at DZ Bank from GBX 1,900 ($23.38) to GBX 1,850 ($22.77) in a report issued on Friday, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the stock. DZ Bank’s price target would indicate a potential upside of 20.93% from the stock’s current price.
A number of other research analysts have also recently issued reports on GSK. Goldman Sachs Group set a GBX 2,060 ($25.35) price objective on GlaxoSmithKline and gave the company a “buy” rating in a report on Wednesday, July 15th. Oddo Securities lifted their price objective on GlaxoSmithKline from GBX 1,760 ($21.66) to GBX 1,840 ($22.64) and gave the company a “neutral” rating in a report on Monday, June 22nd. Credit Suisse Group lowered their target price on GlaxoSmithKline from GBX 1,860 ($22.89) to GBX 1,700 ($20.92) and set a “neutral” rating for the company in a research note on Thursday. Deutsche Bank restated a “hold” rating and issued a GBX 1,600 ($19.69) target price on shares of GlaxoSmithKline in a research note on Monday, April 6th. Finally, Oddo Bhf restated a “neutral” rating and issued a GBX 1,840 ($22.64) target price on shares of GlaxoSmithKline in a research note on Monday, June 22nd. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of GBX 1,832.24 ($22.55).
Shares of LON GSK opened at GBX 1,529.80 ($18.83) on Friday. The stock has a market cap of $76.75 billion and a PE ratio of 14.30. The business has a fifty day moving average of GBX 1,624 and a two-hundred day moving average of GBX 1,636.23. GlaxoSmithKline has a 52-week low of GBX 16.27 ($0.20) and a 52-week high of GBX 1,857 ($22.85). The company has a debt-to-equity ratio of 159.26, a quick ratio of 0.54 and a current ratio of 0.87.
GlaxoSmithKline (LON:GSK) last issued its quarterly earnings data on Wednesday, July 29th. The company reported GBX 56.90 ($0.70) earnings per share (EPS) for the quarter. Analysts predict that GlaxoSmithKline will post 11385.0001492 earnings per share for the current year.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.